Gumokimab
Akeso Advances Non-Oncology Portfolio with Ankylosing Spondylitis Phase III Win
Akeso’s Gumokimab (AK111) achieves pivotal Phase III success in AS, complementing its non-oncology portfolio and boosting potential for domestic market share and future international licensing deals.